Sultana Monira Hussain

Dr. Sultana Monira Hussain


Research Focus & Metrics

Academic Career Length

57Years (1970-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in The Spine Journal
Verified
Journal Article
Closed access
TRTom A. Ranger
Tom A. Ranger
FCFlavia M. Cicuttini
Flavia M. Cicuttini
TJTue S. Jensen
Tue S. Jensen
WPWaruna L. Peiris
Waruna L. Peiris
SHSultana Monira Hussain
Sultana Monira Hussain
DUDonna M. Urquhart
Donna M. Urquhart

30 January 2019 in BMJ
Verified
Journal Article
Open access
PDF file
KSKatherine Sievert
Katherine Sievert
SHSultana Monira Hussain
Sultana Monira Hussain
MPMatthew J Page
Matthew J Page
YWYuanyuan Wang
Yuanyuan Wang
HHHarrison J Hughes
Harrison J Hughes
FCFlavia M. Cicuttini
Flavia M. Cicuttini
Objective: To examine the effect of regular breakfast consumption on weight change and energy intake in people living in high income countries.Design: Systematic review and meta-analysis.Data sources: PubMed, Ovid Medline, and CINAHL were searched for randomised controlled trials published between January 1990 and January 2018 investigating the effect of breakfast on weight or energy intake. ClinicalTrials.gov and the World Health Organization’s International Clinical Trials Registry Platform search portal were also searched in October 2018 to identify any registered yet unpublished or ongoing trials.Eligibility criteria for selecting studies: Randomised controlled trials from high income countries in adults comparing breakfast consumption with no breakfast consumption that included a measure of body weight or energy intake. Two independent reviewers extracted the data and assessed the risk of bias of included studies. Random effects meta-analyses of the effect of breakfast consumption on weight and daily energy intake were performed.Results: Of 13 included trials, seven examined the effect of eating breakfast on weight change, and 10 examined the effect on energy intake. Meta-analysis of the results found a small difference in weight favouring participants who skipped breakfast (mean difference 0.44 kg, 95% confidence interval 0.07 to 0.82), but there was some inconsistency across trial results (I2=43%). Participants assigned to breakfast had a higher total daily energy intake than those assigned to skip breakfast (mean difference 259.79 kcal/day, 78.87 to 440.71; 1 kcal=4.18 kJ), despite substantial inconsistency across trial results (I2=80%). All of the included trials were at high or unclear risk of bias in at least one domain and had only short term follow-ups (mean period seven weeks for weight, two weeks for energy intake). As the quality of the included studies was mostly low, the findings should be interpreted with caution.Conclusion: This study suggests that the addition of breakfast might not be a good strategy for weight loss, regardless of established breakfast habit. Caution is needed when recommending breakfast for weight loss in adults, as it could have the opposite effect. Further randomised controlled trials of high quality are needed to examine the role of breakfast eating in the approach to weight management.Study registration: PROSPERO registration number CRD42017057687.

1 March 2018 in The Clinical Journal of Pain
Verified
Journal Article
Closed access
SNSin Ki Ng
Sin Ki Ng
DUDonna M. Urquhart
Donna M. Urquhart
PFPaul B. Fitzgerald
Paul B. Fitzgerald
FCFlavia M. Cicuttini
Flavia M. Cicuttini
SHSultana Monira Hussain
Sultana Monira Hussain
BFBernadette M. Fitzgibbon
Bernadette M. Fitzgibbon
Objectives: Chronic low back pain (CLBP) is a major health issue, yet its underlying mechanisms remain unknown. Studies have demonstrated the importance of emotion and cognition in chronic pain; however, the relevant brain physiology in magnetic resonance imaging (MRI) studies are unclear in CLBP populations. Therefore, this review aimed to identify MRI brain changes and examine their potential relationship with emotional and cognitive processes in CLBP. Methods: A systematic search was conducted in 5 databases. Studies that recruited adult, CLBP populations, and used brain MRI protocols were included. Results: In total, 55 studies met the inclusion criteria. Of the structural MRI studies, 10 of 15 studies found decreased gray matter and 7 of 8 studies found white matter changes in CLBP groups compared with controls. Fourteen resting-state functional MRI studies all reported differences between CLBP and control groups in the default mode network. Interestingly, only 3 of 10 functional MRI studies observed significant differences during noxious stimulation between CLBP and control groups, whereas 13 of 16 studies observed significant brain activation differences in CLBP groups during various external tasks. Finally, there were 3 studies that observed a degree of recovery in functional connectivity following intervention. Discussion: The brain changes in CLBP groups were mainly observed in areas and networks important in emotion and cognition, rather than those typically associated with nociception. This supports the understanding that emotional and cognitive processes may be the core contributor to the CLBP experience; however, future studies need to explore these processes further.

22 January 2015 in BMC Medicine
Verified
Journal Article
Open access
PDF file
DUDonna M Urquhart
Donna M Urquhart
YZYiliang Zheng
Yiliang Zheng
ACAllen C Cheng
Allen C Cheng
JRJeffrey V Rosenfeld
Jeffrey V Rosenfeld
PCPatrick Chan
Patrick Chan
FCFlavia M. Cicuttini
Flavia M. Cicuttini
Recently, there has been both immense interest and controversy regarding a randomised, controlled trial which showed antibiotics to be effective in the treatment of chronic low back pain (disc herniation with Modic Type 1 change). While this research has the potential to result in a paradigm shift in the treatment of low back pain, several questions remain unanswered. This systematic review aims to address these questions by examining the role of bacteria in low back pain and the relationship between bacteria and Modic change. We conducted electronic searches of MEDLINE and EMBASE and included studies that examined the relationship between bacteria and back pain or Modic change. Studies were rated based on their methodological quality, a best-evidence synthesis was used to summarise the results, and Bradford Hill’s criteria were used to assess the evidence for causation. Eleven studies were identified. The median (range) age and percentage of female participants was 44.7 (41–46.4) years and 41.5% (27–59%), respectively, and in 7 of the 11 studies participants were diagnosed with disc herniation. Nine studies examined the presence of bacteria in spinal disc material and all identified bacteria, with the pooled estimate of the proportion with positive samples being 34%. Propionibacterium acnes was the most prevalent bacteria, being present in 7 of the 9 studies, with median (minimum, maximum) 45.0% (0–86.0) of samples positive. The best evidence synthesis found moderate evidence for a relationship between the presence of bacteria and both low back pain with disc herniation and Modic Type 1 change with disc herniation. There was modest evidence for a cause-effect relationship. We found that bacteria were common in the spinal disc material of people undergoing spinal surgery. There was moderate evidence for a relationship between the presence of bacteria and both low back pain with disc herniation and Modic Type 1 change associated with disc herniation and modest evidence for causation. However, further work is needed to determine whether these organisms are a result of contamination or represent low grade infection of the spine which contributes to chronic low back pain.

1 February 2014 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
SHSultana Monira Hussain
Sultana Monira Hussain
YWYuanyuan Wang
Yuanyuan Wang
FCFlavia M. Cicuttini
Flavia M. Cicuttini
JSJulie A. Simpson
Julie A. Simpson
GGGraham G Giles
Graham G Giles
AWAnita Wluka
Anita Wluka

24 May 2019 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
YWYuanyuan Wang
Yuanyuan Wang
SHSultana Monira Hussain
Sultana Monira Hussain
AWAnita Wluka
Anita Wluka
YLYuan Z. Lim
Yuan Z. Lim
FAFrançois Abram
François Abram
FCFlavia M. Cicuttini
Flavia M. Cicuttini
To examine whether metformin use was associated with knee cartilage volume loss over 4 years and risk of total knee replacement over 6 years in obese individuals with knee osteoarthritis. This study analysed the Osteoarthritis Initiative participants with radiographic knee osteoarthritis (Kellgren-Lawrence grade ≥ 2) who were obese (body mass index [BMI] ≥ 30 kg/m2). Participants were classified as metformin users if they self-reported regular metformin use at baseline, 1-year and 2-year follow-up (n = 56). Non-users of metformin were defined as participants who did not report the use of metformin at any visit from baseline to 4-year follow-up (n = 762). Medial and lateral cartilage volume (femoral condyle and tibial plateau) were assessed using magnetic resonance imaging at baseline and 4 years. Total knee replacement over 6 years was assessed. General linear model and binary logistic regression were used for statistical analyses. The rate of medial cartilage volume loss was lower in metformin users compared with non-users (0.71% vs. 1.57% per annum), with a difference of − 0.86% per annum (95% CI − 1.58% to − 0.15%, p = 0.02), after adjustment for age, gender, BMI, pain score, Kellgren-Lawrence grade, self-reported diabetes, and weight change over 4 years. Metformin use was associated with a trend towards a significant reduction in risk of total knee replacement over 6 years (odds ratio 0.30, 95% CI 0.07–1.30, p = 0.11), after adjustment for age, gender, BMI, Kellgren-Lawrence grade, pain score, and self-reported diabetes. These data suggest that metformin use may have a beneficial effect on long-term knee joint outcomes in those with knee osteoarthritis and obesity. Randomised controlled trials are needed to confirm these findings and determine whether metformin would be a potential disease-modifying drug for knee osteoarthritis with the obese phenotype.